topics / مواضيع: BACKGROUND: The risk of thromboembolism in myelofibrosis remains incompletely understood. OBJECTIVES: To examine the association between

BACKGROUND: The risk of thromboembolism in myelofibrosis remains incompletely understood. OBJECTIVES: To examine the association between

Abstract

BACKGROUND: The risk of thromboembolism in myelofibrosis remains incompletely understood.

OBJECTIVES: To examine the association between myelofibrosis and each of venous and arterial thromboembolism.

METHODS: A cohort of 1,469,790 adults without a diagnosis of myelofibrosis was identified on 1 January 2007, from the electronic medical records of the largest healthcare provider in Israel. Participants were followed-up until 31 December 2016, for the occurrence of myelofibrosis. Four randomly selected controls (without myelofibrosis) were matched to each case of myelofibrosis on age, sex, religious identification and index date. The two groups were followed from the index date until 31 December 2017 for the occurrence of venous and arterial thromboembolism.

RESULTS: The study included 642 patients with myelofibrosis and 2,568 matched controls. Myelofibrosis was independently associated with increased risk of venous thromboembolism but not with arterial thromboembolism. The propensity score adjusted HRs were 6.88 (95% CI, 2.02-23.45) for venous thromboembolism, and 0.94 (0.49-1.77) for arterial thromboembolism. Atypical sites of venous thromboembolism occurred almost exclusively in patients with myelofibrosis (4 events of Budd Chiari versus none, and 2 mesenteric vein thrombosis events versus 1) and were more likely to occur around the time of myelofibrosis diagnosis. No significant association was found between JAK-2 inhibitor treatment (ruxolitinib) and the risk of venous HR 0.97 (0.30-3.12) or arterial thromboembolism 1.68 (0.78-3.62).

CONCLUSIONS: Myelofibrosis is associated with increased risk of venous thromboembolism but not of arterial thromboembolism. Atypical sites of venous thromboembolism are more frequent in myelofibrosis and are more likely to occur shortly after the diagnosis.

PMID: 32017387 [PubMed - as supplied by publisher]

22:13

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

22:13

In reply to this message

pubmed: caandvteortroorpul

External Validation of a Venous Thromboembolic Risk Score for Cancer Outpatients with Solid Tumors: The COMPASS-CAT Venous Thromboembolism Risk Assessment Model.

Oncologist. 2020 Feb 04;:

Authors: Spyropoulos AC, Eldredge JB, Anand LN, Zhang M, Qiu M, Nourabadi S, Rosenberg DJ